Abstract
The incidence of clinically significant complications after protocol biopsy of a stable renal transplant is low. Direct benefits to the patients concerned (irrespective of the benefit that may accrue in clinical trials) were not formally assessed but seem likely to outweigh the risk of the procedure. We believe that it is ethically justifiable to ask renal transplant recipients to undergo protocol biopsies in clinical trials and routine care.
Original language | English |
---|---|
Pages (from-to) | 969-973 |
Number of pages | 5 |
Journal | Transplantation |
Volume | 76 |
Issue number | 6 |
DOIs | |
Publication status | Published - 27 Sep 2003 |